Amy J. Wisdom, Christopher A. Barker, Joe Y. Chang, Sandra Demaria, Silvia Formenti, Clemens Grassberger, Fabiana Gregucci, Bradford S. Hoppe, David G. Kirsch, Ariel E. Marciscano, Jyoti Mayadev, Kent W. Mouw, Manisha Palta, Cheng-Chia Wu, Salma K. Jabbour & Jonathan D. Schoenfeld. (2024) The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives. International Journal of Radiation Oncology*Biology*Physics 118:5, pages 1404-1421.
Crossref
Wenyan Chen, Chen Yang, Biqi Chen, Mian Xi, Baoqing Chen & Qiaoqiao Li. (2024) Management of metastatic bone disease of melanoma. Melanoma Research 34:1, pages 22-30.
Crossref
Blessie Elizabeth Nelson, Jacob J. Adashek, Aakash Akshay Sheth & Vivek Subbiah. (2023) Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers. Molecular Cancer Therapeutics 22:6, pages 706-716.
Crossref
Julien Pierrard, Geneviève Van Ooteghem & Marc Van den Eynde. (2023) Implications of the Organ-Specific Immune Environment for Immune Priming Effect of Radiotherapy in Metastatic Setting. Biomolecules 13:4, pages 689.
Crossref
Ai Sato, Jeffrey Kraynak, Ariel E. Marciscano & Lorenzo Galluzzi. 2023. Radiation Oncology and Radiotherapy Part C. Radiation Oncology and Radiotherapy Part C
xv
xxv
.
Ai Sato, Jeffrey Kraynak, Ariel E. Marciscano & Lorenzo Galluzzi. 2023. Radiation Oncology and Radiotherapy. Radiation Oncology and Radiotherapy
xv
xxv
.
O. Leaman-Alcibar, F. López-Campos, J. Aller, Ana Calín-Lorca, E. Zatarain-Nicolás, M. F. Bande & A. Navarro-Martin. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
32
.
Kaixiao Zhou, Yabo Jiang, Shuang Feng, Tingya Wang, Lili Wang, Jianping Cao & Yang Jiao. (2022) Combining radiation with immune checkpoint inhibitors therapy for HCC: From the alteration of the immune microenvironment by radiotherapy. Radiation Medicine and Protection 3:4, pages 183-189.
Crossref
Kellsye P. Fabian, Joshua T. Kowalczyk, Sandy T. Reynolds & James W. Hodge. (2022) Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation. Cells 11:23, pages 3826.
Crossref
Kathryn H. Brown, Mihaela Ghita, Ludwig J. Dubois, Dirk de Ruysscher, Kevin M. Prise, Frank Verhaegen & Karl T. Butterworth. (2022) A scoping review of small animal image-guided radiotherapy research: Advances, impact and future opportunities in translational radiobiology. Clinical and Translational Radiation Oncology 34, pages 112-119.
Crossref
Claudia Galassi, Yangjingyi Ruan, Ai Sato, Carlos Jiménez-Cortegana, Vanessa Klapp, Norma Bloy, Emma Guilbaud, Giulia Petroni, Aitziber Buqué, Lorenzo Galluzzi & Takahiro Yamazaki. 2022. Radiation Oncology and Radiotherapy Part A. Radiation Oncology and Radiotherapy Part A
145
161
.
Beatriz Álvarez-Abril, Norma Bloy, Claudia Galassi, Ai Sato, Carlos Jiménez-Cortegana, Vanessa Klapp, Artur Aretz, Emma Guilbaud, Aitziber Buqué, Lorenzo Galluzzi & Takahiro Yamazaki. 2022. Radiation Oncology and Radiotherapy Part A. Radiation Oncology and Radiotherapy Part A
17
36
.
Carlos Jiménez-Cortegana, Vanessa Klapp, Norma Bloy, Claudia Galassi, Ai Sato, Takahiro Yamazaki, Aitziber Buqué, Lorenzo Galluzzi & Giulia Petroni. 2022. Radiation Oncology and Radiotherapy Part A. Radiation Oncology and Radiotherapy Part A
1
16
.
Ai Sato, Jeffrey Kraynak, Ariel E. Marciscano & Lorenzo Galluzzi. 2022. Radiation Oncology and Radiotherapy Part A. Radiation Oncology and Radiotherapy Part A
xiii
xxiii
.
Sergio Crovella, Alberto Revelant, Elena Muraro, Ronald Rodrigues Moura, Lucas Brandão, Marco Trovò, Agostino Steffan, Paola Zacchi, Giuliano Zabucchi, Emilio Minatel & Violetta Borelli. (2021) Biological Pathways Associated With the Development of Pulmonary Toxicities in Mesothelioma Patients Treated With Radical Hemithoracic Radiation Therapy: A Preliminary Study. Frontiers in Oncology 11.
Crossref
Takami Okuma, Sadanori Furudate, Yumi Kambayashi, Akira Hashimoto, Setsuya Aiba & Taku Fujimura. (2021) Successful treatment of BRAF/MEK inhibitor‐resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity‐modulated radiotherapy. The Journal of Dermatology 48:9, pages 1419-1422.
Crossref